HTR1A and cancer: Additionally, mitragynine’s partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors may offer mood-enhancing and anxiolytic benefits, which are crucial for the overall well-being of cancer patients [10,21].